Maruja Lira's Biography

Maruja Lira, Senior Scientist, Pfizer Inc

Maruja Lira is a senior scientist within Precision Medicine group at Pfizer oncology research unit. Her current focus is on identification of patient selection biomarkers through genomic molecular profiling efforts. She has extensive technical experience in analysis of gene expression, copy number, mutation detection, and next generation sequencing. She is a key developer of a transcript-based assay for screening ALK, ROS1, and RET fusions in lung cancer.

ALK, ROS1 and RET Fusion Detection in Lung Cancer

Thursday, 12 September 2013 at 17:15

Add to Calendar ▼2013-09-12 17:15:002013-09-12 18:15:00Europe/LondonALK, ROS1 and RET Fusion Detection in Lung CancerPoint-of-Care Diagnostics World Congress 2013 in San Diego, CA, USASan Diego, CA, USASELECTBIOenquiries@selectbiosciences.com

~7% of non-small cell lung carcinomas (NSCLC) harbor oncogenic fusions involving ALK, ROS1 and RET. We developed and validated a single-tube multiplex assay to detect the three fusions. Our test shows promise as a more practical and cost-effective screening modality for detection of rare but targetable fusions in lung cancer.

Add to Calendar ▼2013-09-12 00:00:002013-09-13 00:00:00Europe/LondonPoint-of-Care Diagnostics World Congress 2013Point-of-Care Diagnostics World Congress 2013 in San Diego, CA, USASan Diego, CA, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors